32.28
-1.69 (-4.97%)
| Previous Close | 33.97 |
| Open | 33.98 |
| Volume | 960,325 |
| Avg. Volume (3M) | 1,063,733 |
| Market Cap | 2,533,723,904 |
| Price / Sales | 2.41 |
| Price / Book | 5.40 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2026 |
| Operating Margin (TTM) | -9,027.19% |
| Diluted EPS (TTM) | -2.70 |
| Quarterly Revenue Growth (YOY) | 345.50% |
| Total Debt/Equity (MRQ) | 0.49% |
| Current Ratio (MRQ) | 21.67 |
| Operating Cash Flow (TTM) | -171.51 M |
| Levered Free Cash Flow (TTM) | -101.09 M |
| Return on Assets (TTM) | -16.88% |
| Return on Equity (TTM) | -23.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Celldex Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.13 |
|
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.32% |
| % Held by Institutions | 113.13% |
| 52 Weeks Range | ||
| Median | 34.00 (5.33%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 02 Mar 2026 | 34.00 (5.33%) | Hold | 30.00 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |